# Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

> **NCT01713855** · NA · COMPLETED · sponsor: **Neufeld, Ellis J, MD, PhD** · enrollment: 10 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura
- Immune Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Inactivated Trivalent Influenza vaccine

## Key facts

- **NCT ID:** NCT01713855
- **Lead sponsor:** Neufeld, Ellis J, MD, PhD
- **Sponsor class:** INDIV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713855, "Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01713855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*